Search results for "Akt inhibitor"

3 results for "Akt inhibitor" - showing 1-3

Display

< >

<< Previous Next >>

Application Data (At 25 degree C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37 degree C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody.)

IHC (Immunohistchemistry) (At 1/200 staining Mouse kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22 degree C. An HRP conjugated goat anti-rabbit antibody was used as the secondary antibody.)

IHC (Immunohistochemistry) (At 1/200 staining Rat kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22 degree C. An HRP conjugated goat anti-rabbit antibody was used as the secondary antibody.)

IHC (Immunohistochemistry) (At 1/200 staining Human kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22 degree C. An HRP conjugated goat anti-rabbit antibody was used as the secondary antibody.)

IHC (Immunohistochemistry) (At 1/200 staining Mouse brain tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22 degree C. An HRP conjugated goat anti-rabbit antibody was used as the secondary antibody.)

WB (Western Blot) (Western blot analysis of p27 Kip1 (Phospho-Thr157) using HeLa whole cell lysates.-/+ means absence or presence of N peptide（non-phospho peptide) and P peptide(phospho peptide).)

WB (Western Blot) (Western blot analysis of extracts from rat brain, using p27 Kip1 (Phospho-Thr157) Antibody. Lane 1 was treated with the blocking peptide.)

p27 Kip1, Polyclonal Antibody (Cat# AAA31387)

Full Name

Phospho-p27 Kip1 (Thr157) Antibody

Gene Names

CDKN1B; KIP1; MEN4; CDKN4; MEN1B; P27KIP1

Reactivity

Human, Mouse, Rat
Predicted Reactivity: Bovine (89%), Sheep (89%), Rabbit (100%), Dog (100%), Chicken (89%)

Applications

WB, IHC, IF, ICC, EIA

Purity

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

< >

<< Previous Next >>

IHC (Immunohistochemistry) (At 1/200 staining Human breast tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22 degree C. An HRP conjugated goat anti-rabbit antibody was used as the secondary antibody.)

IHC (Immunohistochemistry) (At 1/200 staining Mouse kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22 degree C. An HRP conjugated goat anti-rabbit antibody was used as the secondary antibody.)

WB (Western Blot) (Western blot analysis of p27 Kip1 (Phospho-Ser178) using EGF treated HepG2 whole cell lysates.-/+ means absence or presence of N peptide（non-phospho peptide) and P peptide(phospho peptide).)

WB (Western Blot) (Western blot analysis of extracts from rat brain, using p27 Kip1 (Phospho-Ser178) Antibody. Lane 1 was treated with the blocking peptide.)

p27 Kip1, Polyclonal Antibody (Cat# AAA31388)

Full Name

Phospho-p27 Kip1 (Ser178) Antibody

Gene Names

CDKN1B; KIP1; MEN4; CDKN4; MEN1B; P27KIP1

Reactivity

Human, Mouse, Rat
Predicted Reactivity: Bovine (100%), Sheep (100%), Rabbit (100%), Dog (100%)

Applications

WB, IHC, IF, ICC, EIA

Purity

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

< >

<< Previous Next >>

Application Data (Published customer imageSLAMF3 blockade in human hepatocytes is associated with lower susceptibility to HCV. (A) SLAMF3 was stained in primary human hepatocytes (PHHs) and cells from the Huh-7 human hepatoma cell line with a specific antibody (HLy9.1.25 clone; grey) and an isotype-matched control (empty). One of four independent experiments is shown. Huh-7 cells were transfected with scrambled control (sc) siRNA or three specific siRNAs (#1, #2 and #3) targeting SLAMF3, prior to infection with HCVcc; siRNA efficiency was checked by quantifying SLAMF3 mRNA (B) and the CD81 expression level (C) by flow cytometry analysis at 48 h post-transfection. Results are presented as the mean +/-SD (n = 3). Intracellular viral RNA was quantified at 72 h p.i. (D) and the infection was measured at 72 h p.i. by focus-forming units FFUs counting (E) (as inhibition percent; mean of three independent experiments; error bars: SD. **p)

Application Data (Published customer image: Effect of SLAMF3 expression on the organization of the actin cytoskeleton. Cells (Huh-7) were stained with phalloidin (rhodamine, red) and anti-SLAMF3 (FITC, green) and SLAMF3 positive (Huh-7-SLAMF3pos) and SLAMF3-negative (Huh-7-SLAMF3pos) cells were examined under the microscope. One representative of two independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)

Application Data (Published customer image: Expression of SLAM-R family by HHPHs and Huh-7 and HepG2 human HCC cell lines. SLAM-Rs were stained with specific antibodies against SLAMF1 (CD150), SLAMF2 (CD84), SLAMF4 (CD224) and SLAMF6 (NTBA) (grey) or with matched isotype controls (empty). One of four independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)

Application Data (Published customer image: Expression of SLAMF3 assessed by flow cytometry analysis after transfection with vector coding for SLAMF3 or an empty vector (Mock) in Huh-7 and HepG2 cells. SLAMF3 staining (in grey) is overlaid by negative control (in white). One of four independent experiments is shown. doi:10.1371/journal.pone.0082918.s002From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)

Application Data (Published customer image: Restoration of SLAMF3 expression in HCC cells inhibits MAPK ERK1/2, JNK and mTOR pathways and induces caspase-dependent apoptosis.(A) SLAMF3 expression was confirmed by Western blot analysis in SLAMF3-over-expressing Huh-7 and mock cells at 48 h post-transfection. ERK1/2, JNK, p38, AKT and mTOR proteins were detected as controls. The activation levels of MAPK ERK1/2 (Thr 202/Tyr 204), JNK (Thr 183/Tyr 185), p38 (Thr 180/Tyr 183), PI3K (p85/p110 Thr 467/Tyr 199), AKT (Ser 473, Thr 308) and mTOR (Ser 2448, Ser 2481) are represented. One of three representative experiments is shown here. (B) The results of an active caspase assay based on cell-permeable fluorochrome inhibitor of caspases (FLICA). Caspase activity was evaluated in HCC cells (Huh-7 and HepG2 lines) at the indicated times after the ectopic introduction of SLAMF3 vector. Caspase activity is shown in the SLAMF3neg subpopulation (in white) and the SLAMF3pos (overlaid in grey) subpopulation from one representative of two independent experiments.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)

Application Data (Published customer image: SLAMF3 expression is repressed in tumour cells from ten resected HCC patients. (A) SLAMF3 mRNA expression was analysed in hepatocytes from resected HCC patients. Specific amplification of SLAMF3 mRNAs using PCR (representative patients #2, #7 and #12) and quantitative PCR in tumour tissues (T) and peritumoral tissues (pT) presented separately (B) and as median (**p)

Application Data (Published customer image SLAMF3 over-expression increases hepatocyte permissiveness to HCV. Huh-7 cells were transfected with empty vector pBud (mock) or human SLAMF3 (to yield Huh-7+ cells) and incubated with HCVcc. (A) SLAMF3 expression was analyzed by flow cytometry (HLy9.1.25 clone) and (B) visualized by confocal microscopy in one out of three experiment. Unshaded histograms show the isotype-matched control (Co) and shaded histograms show SLAMF3 expression). (C, D, E) Infection was assessed at 4 and 72 h p.i. as the number of FFUs and (F and G) by flow cytometry analysis; (C) intracellular E2 (stained red) were measured at 4 h and 72 h p.i. Green staining corresponds to the SLAMF3 expression. One of three representatives independent experiments is shown. (D) The HCV permissiveness of Huh-7 mock and Huh-7+ cells was evaluated in terms of the number of FFUs based on intracellular E2 viral protein staining and (E) fluorescent microscopy analysis (mean of five experiments; error bars: SD; *p)

Application Data (Staining of human peripheral blood lymphocytes with Mouse anti Human CD229 : RPE)

Application Data (Published customer image: Correlation between SLAMF3 expression and HCC cell proliferation.(A) Effects of the introduction of specific siRNAs on SLAMF3 expression in Huh-7 cells. Cells were transiently transfected with a scrambled siRNA (Sc) or one of two pre-designed anti-SLAMF3 siRNAs (referred to as #2 and # 3); SLAMF3 expression was measured by Western blot analysis (anti-SLAMF3, K12). One representative of two independent experiments is shown. (B) siRNA-treated Huh-7 cells were cultured and proliferation was assayed in a Trypan blue exclusion test after 48 h. Proliferation is presented as the mean number of viable cells +/- SD (n = 5; statistical significance: ***p)

Application Data (Staining of human peripheral blood lymphocytes with Mouse anti Human CD299: Azide Free)

CD229, Monoclonal Antibody (Cat# AAA11951)

Full Name

MOUSE ANTI HUMAN CD229

Gene Names

LY9; hly9; mLY9; CD229; SLAMF3

Applications

FC/FACS, IP

Loading...

Filters

Clonality

Type

Reactivity

Gene Name

Isotype

Host

Application

Clone

3 results for "Akt inhibitor" - showing 1-3

p27 Kip1, Polyclonal Antibody (Cat# AAA31387)

p27 Kip1, Polyclonal Antibody (Cat# AAA31388)

CD229, Monoclonal Antibody (Cat# AAA11951)

Contact us by

Loading...

Filters

Clonality

Type

Reactivity

Gene Name

Isotype

Host

Application

Clone

3 results for "Akt inhibitor" - showing 1-3

p27 Kip1, Polyclonal Antibody (Cat# AAA31387)

p27 Kip1, Polyclonal Antibody (Cat# AAA31388)

CD229, Monoclonal Antibody (Cat# AAA11951)

Contact us by

Request more Information

Request a Manual

Request a Quote